{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:10:46Z","timestamp":1780791046598,"version":"3.54.1"},"reference-count":6,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T00:00:00Z","timestamp":1423612800000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.jacc.2013.09.048","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T22:00:36Z","timestamp":1382565636000},"page":"430-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["AMG 145, a Monoclonal Antibody Against PCSK9, Facilitates Achievement of National Cholesterol Education Program\u2013Adult Treatment Panel III Low-Density Lipoprotein Cholesterol Goals Among High-Risk Patients"],"prefix":"10.1016","volume":"63","author":[{"given":"Nihar R.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ransi","family":"Somaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.09.048_bib1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.09.048_bib2","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.2009.1672","article-title":"Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999\u20132006","volume":"302","author":"Kuklina","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.09.048_bib3","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.amjcard.2010.11.006","article-title":"Achieving optimal lipid goals in patients with coronary artery disease","volume":"107","author":"Karalis","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.09.048_bib4","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.09.048_bib5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT\u2013TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.09.048_bib6","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713056088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713056088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:05:14Z","timestamp":1760015114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713056088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0735109713056088"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.09.048","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AMG 145, a Monoclonal Antibody Against PCSK9, Facilitates Achievement of National Cholesterol Education Program\u2013Adult Treatment Panel III Low-Density Lipoprotein Cholesterol Goals Among High-Risk Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.09.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}